The FDA approved tiratricol (Emcitate) for peripheral thyrotoxicosis in MCT8 deficiency, the first approved therapy for the rare disorder.
News|Articles|February 18, 2026
International guideline recommends sebetralstat as first-line acute therapy for adolescents with hereditary angioedema
Author(s)Morgan Ebert, Executive Editor
Fact checked by: Celeste Krewson, Assistant Editor, Kelly King
New international pediatric HAE guideline recommends oral sebetralstat as first-line acute therapy for adolescents 12 years and older.
Advertisement
Advertisement
A newly published international guideline on the diagnosis and management of pediatric hereditary angioedema (HAE) provides updated, evidence-based recommendations for children and adolescents with HAE due to C1 inhibitor deficiency (HAE-C1INH), including a strong recommendation for sebetralstat as a first-line option for acute treatment in adolescents 12 years and older.1,2
Related to this article
FDA approves oral ALK2 inhibitor zilurgisertib for FOP in patients 12+, based on phase 2 PROGRESS data on new heterotopic ossification volume.
FDA approved obinutuzumab for relapsing or steroid-dependent childhood-onset INS, based on INShore data showing 95.5% vs 73.2% sustained remission.
Lavengratinib increased annualized height velocity in 7 children with achondroplasia, but open-label phase 2 findings remain preliminary.
The FDA granted satralizumab priority review for MOGAD after phase 3 findings showed a 68% reduction in relapse risk versus placebo.
The FDA accepted the dersimelagon NDA with priority review for EPP and XLP; a decision on the oral MC1R agonist is expected by February 2027.
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), a one-time AAV9 gene therapy, as the first treatment for pediatric MPS IIIA (Sanfilippo syndrome type A).
The FDA approved 40 mg and 50 mg twice-daily leniolisib (Joenja) for children ages 4 to 11 years weighing at least 27 kg with activated PI3Kδ syndrome.
Advertisement
Advertisement